Actavis’ (ACT) Antibiotic Receives FDA’s Advisory Committee Recommendation

December 6, 2014 2:36 PM

11 0

Actavis announced Friday that its experimental drug ceftazidime-avibactam received FDA's Advisory Committee recommendation, to treat patients with cIAI and cUTI

Yesterday, Actavis plc (NYSE:ACT) announced that its experimental antibiotic, ceftazidime-avibactam, has been recommended by the US Food & Drug’s (FDA) Anti-Infective Drugs Advisory Committee, for use in treating complicated intra-abdominal infections (cIAI) and complicated urinary tract infections ...

Read more

To category page